医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PDA India Chapter Annual Meeting – Maintaining Quality & Compliance in Pharmaceutical Drug Manufacturing and Regulatory Expectations – Being Held March 11-15, in Hyderabad, India

2024年03月04日 AM11:27
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

PQE Group is excited to join the 2024 PDA India Chapter Annual Meeting in Hyderabad from March 11-15, focusing on key issues in the pharmaceutical and medical device industries.

The conference will cover environmental monitoring, aseptic processing, cleaning validation, cross-contamination, and compliance strategies in the pharma and medical device industries, with insights from regulators and experts on technologies, data integrity, and quality enhancement.

On the first day of the conference, the opening plenary sessions will feature opening remarks from Dr. Sarah McMullen, Country Director, US FDA India Office, Alonza Cruse, Director, Office of Pharmaceutical Quality Operations, ORA/FDA, Dr. Anil Sawant, Senior Vice President, Global Quality Compliance, Merck Sharpe & Dohme, USA and Chair, Board of Directors, PDA Inc, a Regulatory Update will be provided by Dr. Carmelo Rosa, Director Division of Drug Quality I, CDER/OMQ/US FDA and Co-Chair, PDA India Chapter and many other exciting regulatory presenters. Annual Meeting Day One will also focus on Quality Culture, with sessions including topics regarding several aspects of the importance of Quality Culture, Quality Sustainability, and Quality Maturity, which will be led by presenters including Dr. Rosa, Dr. G.K. Raju, Chairman and CEO, Light Pharma Inc., Stephen Tyrpak, Vice President Operations, PQE US Inc, and Dr. Deva Puranam, Head – Global Quality Investigations, Surveillance & Regulatory Communications, Viatris.

The “Back to Basics” workshop on March 14-15, hosted by US FDA and industry experts, will discuss key regulations and guidelines to help participants understand regulatory expectations for sustainable operations. In addition, Stephen Tyrpak will lead sessions on Quality Culture, risk management, and visual inspections with case studies and demos. FDA and EDQM regulators, along with other experts, will conduct various sessions throughout the conference.

“We’re thrilled to take part, present, and support this significant event, which has become increasingly valuable for the pharmaceutical and medical device industries in India. Since PQE Group’s launch in India in 2019, we’ve grown to over 110 professionals dedicated to compliance across the region. We eagerly anticipate a productive and educational week in Hyderabad, looking forward to reconnecting with peers and forging new partnerships at booth #7.” said Mahesh Jagtap, PQE India local partner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240303061463/en/

CONTACT

Media Contact:

Debra Kaufmann – d.kaufmann@pqegroup.com; +1.240.704.0550

同じカテゴリーの記事 

  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
  • Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
  • Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
  • BrainChip Earns Australian Patent for Improved Spiking Neural Network
  • Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies